Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center

BACKGROUND AND AIM: Anti‐tumor necrosis factor alpha (TNFα) therapies have improved outcomes for patients with inflammatory bowel disease. The aim of this study was to explore the relationship between infliximab (IFX) and adalimumab (ADL) trough and antibody levels with clinical response rates at th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tighe, Donal, Smith, Sinead, O'Connor, Anthony, Breslin, Niall, Ryan, Barbara, McNamara, Deirdre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207032/
https://www.ncbi.nlm.nih.gov/pubmed/30483525
http://dx.doi.org/10.1002/jgh3.12000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207032/
https://www.ncbi.nlm.nih.gov/pubmed/30483525
http://dx.doi.org/10.1002/jgh3.12000

Ejemplares similares